Stanford researchers pursue AnaptysBio's embattled IL-33 drug in peanut allergy

Backed by promising results from a small clinical study, Stanford University scientists are investigating the potential for treating peanut allergy with one injection of AnaptysBio’s anti-IL-33 etokimab, a drug that recently suffered a trial setback in eczema.